Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer’s disease

[1]  Xiaojing Sui,et al.  Cerebrospinal fluid biomarkers of Alzheimer’s disease , 2014, Neuroscience Bulletin.

[2]  A. Kurz,et al.  The National Institute on Aging-Alzheimer’s Association research criteria for mild cognitive impairment due to Alzheimer’s disease: predicting the outcome , 2013, European Archives of Psychiatry and Clinical Neuroscience.

[3]  F. Jessen,et al.  Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease , 2012, Neurology.

[4]  C. Jack,et al.  Evidence for ordering of Alzheimer disease biomarkers. , 2011, Archives of neurology.

[5]  R. Honea,et al.  Alzheimer disease biomarkers are associated with body mass index , 2011, Neurology.

[6]  K. Rufibach,et al.  Modeling of Pathological Traits in Alzheimer's Disease Based on Systemic Extracellular Signaling Proteome* , 2011, Molecular & Cellular Proteomics.

[7]  R. Hamilton,et al.  Diversity and Disparity in Dementia: The Impact of Ethnoracial Differences in Alzheimer Disease , 2011, Alzheimer disease and associated disorders.

[8]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[9]  Chengjie Xiong,et al.  Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer's Disease Diagnosis and Prognosis , 2011, PloS one.

[10]  J. Provias,et al.  Correlation analysis of capillary APOE, VEGF and eNOS expression in Alzheimer brains. , 2011, Current Alzheimer research.

[11]  Robert A. Dean,et al.  Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI , 2011, Acta Neuropathologica.

[12]  K. Blennow,et al.  Screening for New Biomarkers for Subcortical Vascular Dementia and Alzheimer's Disease , 2011, Dementia and Geriatric Cognitive Disorders Extra.

[13]  P. Calabresi,et al.  CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. , 2011, Journal of Alzheimer's Disease.

[14]  S. Potkin,et al.  Genome-wide association study of CSF biomarkers Aβ1-42, t-tau, and p-tau181p in the ADNI cohort , 2010, Neurology.

[15]  J. Storch,et al.  Tissue-specific Functions in the Fatty Acid-binding Protein Family* , 2010, The Journal of Biological Chemistry.

[16]  Murray Grossman,et al.  Biomarker discovery for Alzheimer’s disease, frontotemporal lobar degeneration, and Parkinson’s disease , 2010, Acta Neuropathologica.

[17]  K. Eguchi,et al.  Development of an Ultra-Rapid Diagnostic Method Based on Heart-Type Fatty Acid Binding Protein Levels in the CSF of CJD Patients , 2010, Cellular and Molecular Neurobiology.

[18]  C. Jack,et al.  Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects , 2010, Alzheimer's & Dementia.

[19]  Dolores Catelan,et al.  Multiple testing in disease mapping and descriptive epidemiology. , 2010, Geospatial health.

[20]  Murray Grossman,et al.  Novel CSF biomarkers for Alzheimer’s disease and mild cognitive impairment , 2010, Acta Neuropathologica.

[21]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[22]  D. Martins‐de‐Souza.  Is the word ‘biomarker’ being properly used by proteomics research in neuroscience? , 2010, European Archives of Psychiatry and Clinical Neuroscience.

[23]  Madhav Thambisetty,et al.  Blood-based biomarkers of Alzheimer's disease: challenging but feasible. , 2010, Biomarkers in medicine.

[24]  Reinhard Schliebs,et al.  Vascular endothelial growth factor (VEGF) affects processing of amyloid precursor protein and β-amyloidogenesis in brain slice cultures derived from transgenic Tg2576 mouse brain , 2009, International Journal of Developmental Neuroscience.

[25]  P. Carmeliet,et al.  Role and therapeutic potential of VEGF in the nervous system. , 2009, Physiological reviews.

[26]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[27]  E. Umlauf,et al.  The role of proteomics in dementia and Alzheimer’s disease , 2009, Acta Neuropathologica.

[28]  Jing Zhang,et al.  CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. , 2008, American journal of clinical pathology.

[29]  P. Lewczuk,et al.  Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases. , 2008, Methods.

[30]  J. Wiltfang,et al.  Serum Heart-Type Fatty Acid-Binding Protein and Cerebrospinal Fluid Tau: Marker Candidates for Dementia with Lewy Bodies , 2007, Neurodegenerative Diseases.

[31]  H. Hinterhuber,et al.  Measurement of Thirteen Biological Markers in CSF of Patients with Alzheimer’s Disease and Other Dementias , 2005, Dementia and Geriatric Cognitive Disorders.

[32]  F. Spener,et al.  Release of brain–type and heart–type fatty acid–binding proteins in serum after acute ischaemic stroke , 2005, Journal of Neurology.

[33]  G. Román.  Vascular dementia. Advances in nosology, diagnosis, treatment and prevention. , 2004, Panminerva medica.

[34]  P. Lewczuk,et al.  Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases , 2004, Neuroscience Letters.

[35]  A. Twijnstra,et al.  Brain- and heart-type fatty acid-binding proteins in the brain: tissue distribution and clinical utility. , 2004, Clinical chemistry.

[36]  Yong Song Gho,et al.  Co-accumulation of vascular endothelial growth factor with β-amyloid in the brain of patients with Alzheimer’s disease , 2004, Neurobiology of Aging.

[37]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Anders Wallin,et al.  Increased intrathecal levels of the angiogenic factors VEGF and TGF-β in Alzheimer’s disease and vascular dementia , 2002, Neurobiology of Aging.

[39]  J. Veerkamp,et al.  Fatty acid-binding proteins of nervous tissue , 2001, Journal of Molecular Neuroscience.

[40]  P. Deyn,et al.  Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.

[41]  B. Thies,et al.  Consensus report of the Working Group on: molecular and biochemical markers of Alzheimer's disease. , 1999 .

[42]  J. LaManna,et al.  Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia. , 1998, Brain research. Molecular brain research.

[43]  Giovanni B. Frisoni,et al.  Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' , 1998 .

[44]  J. Morris,et al.  Validation of clinical diagnostic criteria for Alzheimer's disease , 1988, Annals of neurology.

[45]  P. Lescuyer,et al.  Heart-Fatty Acid-Binding Protein as a Marker for Early Detection of Acute Myocardial Infarction and Stroke , 2012, Molecular Diagnosis.

[46]  K. Blennow,et al.  Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[47]  N. Stocchetti,et al.  Increased levels of CSF heart-type fatty acid-binding protein and tau protein after aneurysmal subarachnoid hemorrhage. , 2008, Acta neurochirurgica. Supplement.

[48]  Werner Zolg,et al.  The Proteomic Search for Diagnostic Biomarkers IN TRANSLATION , 2006 .

[49]  G. Lubec,et al.  Heart type fatty acid binding protein (H-FABP) is decreased in brains of patients with Down syndrome and Alzheimer's disease. , 2003, Journal of neural transmission. Supplementum.

[50]  Nancy Reagan,et al.  Consensus Report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease" , 1998 .

[51]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .